BR112012003085B1 - Método para obtenção de 3a-hidroxi, 3ss- metil-5a-pregnado-20-ona ( ganaxolona ) - Google Patents

Método para obtenção de 3a-hidroxi, 3ss- metil-5a-pregnado-20-ona ( ganaxolona ) Download PDF

Info

Publication number
BR112012003085B1
BR112012003085B1 BR112012003085-0A BR112012003085A BR112012003085B1 BR 112012003085 B1 BR112012003085 B1 BR 112012003085B1 BR 112012003085 A BR112012003085 A BR 112012003085A BR 112012003085 B1 BR112012003085 B1 BR 112012003085B1
Authority
BR
Brazil
Prior art keywords
ganaxolone
methyl
methylating agent
dione
organometallic methylating
Prior art date
Application number
BR112012003085-0A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112012003085A2 (pt
Inventor
Alan Hutchison
Kenneth Shaw
Original Assignee
Marinus Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marinus Pharmaceuticals, Inc. filed Critical Marinus Pharmaceuticals, Inc.
Publication of BR112012003085A2 publication Critical patent/BR112012003085A2/pt
Publication of BR112012003085B1 publication Critical patent/BR112012003085B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112012003085-0A 2009-08-13 2010-08-11 Método para obtenção de 3a-hidroxi, 3ss- metil-5a-pregnado-20-ona ( ganaxolona ) BR112012003085B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23355309P 2009-08-13 2009-08-13
US61/233,553 2009-08-13
PCT/US2010/045176 WO2011019821A2 (en) 2009-08-13 2010-08-11 METHOD FOR MAKING 3α-HYDROXY, 3β- METHYL-5α-PREGNAN-20-ONE (GANAXOLONE)

Publications (2)

Publication Number Publication Date
BR112012003085A2 BR112012003085A2 (pt) 2020-12-01
BR112012003085B1 true BR112012003085B1 (pt) 2021-06-01

Family

ID=43586809

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012003085-0A BR112012003085B1 (pt) 2009-08-13 2010-08-11 Método para obtenção de 3a-hidroxi, 3ss- metil-5a-pregnado-20-ona ( ganaxolona )

Country Status (14)

Country Link
US (1) US8362286B2 (cg-RX-API-DMAC7.html)
EP (1) EP2464653B1 (cg-RX-API-DMAC7.html)
JP (1) JP5745517B2 (cg-RX-API-DMAC7.html)
KR (1) KR101778603B1 (cg-RX-API-DMAC7.html)
CN (1) CN102549007B (cg-RX-API-DMAC7.html)
AU (1) AU2010282570B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012003085B1 (cg-RX-API-DMAC7.html)
CA (1) CA2769820C (cg-RX-API-DMAC7.html)
EA (1) EA024269B1 (cg-RX-API-DMAC7.html)
ES (1) ES2524724T3 (cg-RX-API-DMAC7.html)
IL (1) IL217857A (cg-RX-API-DMAC7.html)
MX (1) MX2012001728A (cg-RX-API-DMAC7.html)
NZ (1) NZ597940A (cg-RX-API-DMAC7.html)
WO (1) WO2011019821A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2812250T3 (es) 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
US9629853B2 (en) 2014-05-21 2017-04-25 Wisconsin Alumni Research Foundation Uses of ganaxolone
CZ305837B6 (cs) * 2015-02-25 2016-03-30 Vysoká škola chemicko - technologická v Praze (3α,5β,20S)-3-Nitrooxy-pregnan-20-karboxylová kyselina
KR20180082457A (ko) * 2015-10-16 2018-07-18 마리누스 파마슈티컬스 인코포레이티드 나노입자들을 포함하는 주사용 뉴로스테로이드 제제들
CN106366149B (zh) * 2016-08-09 2018-01-23 南京臣功制药股份有限公司 一种醋酸甲羟孕酮分散片的有关物质及其分析检测方法
CN106279326A (zh) * 2016-08-09 2017-01-04 南京臣功制药股份有限公司 一种醋酸甲羟孕酮胶囊的有关物质及其分析检测方法
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
IT201800009683A1 (it) * 2018-10-22 2020-04-22 Ind Chimica Srl Processo per la preparazione di 3α-idrossi-5α-pregnan-20-one (brexanolone)
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
EP4009982A4 (en) 2019-08-05 2023-08-09 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS
AU2020395254B2 (en) 2019-12-06 2026-04-02 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
IT202000021316A1 (it) * 2020-09-09 2022-03-09 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI (3α,5α)-3-IDROSSI-3-METIL-PREGNAN-20-ONE (GANAXOLONE)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953429A (en) * 1970-12-17 1976-04-27 Glaxo Laboratories Limited Anaesthetic steroids of the androstance and pregnane series
US5319115A (en) 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
JP4008024B2 (ja) * 1993-05-24 2007-11-14 パーデュー、ファーマ、リミテッド、パートナーシップ Gabaaレセプター複合体と相互作用させるための化合物
FR2720747B1 (fr) * 1994-06-02 1996-07-12 Roussel Uclaf Nouveau procédé de préparation d'un stéroïde 16béta-méthyl et nouveaux intermédiaires.
BR9509764A (pt) * 1994-11-23 1998-07-07 Cocensys Inc Série androstano e pregnano para modulação alostérica de receptor de gaba
WO2006010085A1 (en) * 2004-07-09 2006-01-26 Roxro Pharma, Inc. Use of neurosteroids to treat neuropathic pain
ES2812250T3 (es) * 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas

Also Published As

Publication number Publication date
IL217857A (en) 2016-03-31
WO2011019821A3 (en) 2011-06-16
WO2011019821A2 (en) 2011-02-17
US8362286B2 (en) 2013-01-29
US20110040112A1 (en) 2011-02-17
EA201270241A1 (ru) 2013-09-30
EP2464653B1 (en) 2014-10-22
CN102549007B (zh) 2015-03-18
BR112012003085A2 (pt) 2020-12-01
JP5745517B2 (ja) 2015-07-08
JP2013501803A (ja) 2013-01-17
KR20120084715A (ko) 2012-07-30
KR101778603B1 (ko) 2017-09-14
AU2010282570B2 (en) 2014-04-24
EA024269B1 (ru) 2016-09-30
CA2769820C (en) 2017-06-27
AU2010282570A1 (en) 2012-02-23
EP2464653A4 (en) 2013-01-16
MX2012001728A (es) 2012-06-01
IL217857A0 (en) 2012-03-29
CA2769820A1 (en) 2011-02-17
EP2464653A2 (en) 2012-06-20
HK1171761A1 (en) 2013-04-05
NZ597940A (en) 2013-03-28
ES2524724T3 (es) 2014-12-11
CN102549007A (zh) 2012-07-04

Similar Documents

Publication Publication Date Title
BR112012003085A2 (pt) método para obtenção de 3x-hidroxi, bb-metil-5x-pregnano-20-ona.
KR102526632B1 (ko) 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 5β-6-알킬-7-하이드록시-3-온 스테로이드
KR102546748B1 (ko) 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-3,7-다이온 스테로이드
ITMI20121344A1 (it) Processo di preparazione di acido ursodesossicolico ad elevata purezza
HK125196A (en) Novel steroid derivatives
EP3645548B1 (en) Methods for preparing bile acids
BR112014008671B1 (pt) Processos de preparação de abiraterona e de acetato de abiraterona, e, composto intermediário
HU216195B (hu) Új eljárás finasteride előállítására
ES2576231T3 (es) Proceso para alquinilar 17-cetoesteroides 16-sustituidos
JP2000514058A (ja) 9α,21―ジハロ―プレグナン―11β,17α―ジオール―20―オンの17―エステルの調製のためのプロセス
BR112021002523A2 (pt) método para preparar um composto
ES2804710T3 (es) Cristal de sal sódica de ácido fosfónico cíclico y método para fabricar el mismo
JP2863715B2 (ja) エステル及びエステル交換可能キサンテートの合成のために有用な方法及び反応体
ES2881336T3 (es) Procedimiento y nuevos productos intermedios para la preparación de 11-metilen-esteroides
CN106083971A (zh) 一种(E)‑3α‑羟基‑6‑亚乙基‑7‑酮‑5β‑胆烷‑24‑酸的制备方法
JPS6044319B2 (ja) 新規なステロイド誘導体の製造法
CH719319B1 (it) Processo per la preparazione di 21-(acetilossi)-17-(1-ossopropossi)-pregn-4-ene-3,20-dione
HK1171761B (en) METHOD FOR MAKING 3α-HYDROXY, 3β- METHYL-5α-PREGNAN-20-ONE (GANAXOLONE)
Jones 3.5. 2 Using NFSI (1) as the Electrophilic Fluorine Source

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07J 5/00 , A61K 31/575 , C07J 9/00 , A61P 25/28 , A61K 31/57

Ipc: A61K 31/575 (2006.01), C07J 5/00 (2006.01), C07J 9

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/08/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF